Previous Close | 0.9469 |
Open | 0.9500 |
Bid | 0.0000 x 800 |
Ask | 0.0000 x 3000 |
Day's Range | 0.9177 - 0.9700 |
52 Week Range | 0.3200 - 3.9200 |
Volume | |
Avg. Volume | 645,190 |
Market Cap | 104.94M |
Beta (5Y Monthly) | 2.72 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.2660 |
Earnings Date | Mar 23, 2022 - Mar 28, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.00 |
Increased product revenue by 17% to $2.0 million; Grew OVA1plus volume by 19% to 5,411 units Entered into a research agreement with Harvard’s Dana Farber Cancer Institute, Brigham & Women’s Hospital, and Medical University of Lodz for development of a diagnostic test for endometriosis Reduced cash utilization by $3.9 Million in the Second Quarter 2022 Conference Call and Webcast scheduled for today, August 10th at 8:30 a.m. ET AUSTIN, Texas, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Healt
AUSTIN, Texas, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced that the company will report its financial results for the second quarter ended June 30, 2022 before the market open on Wednesday, August 10, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 8:30am Eastern Time. Details for the call are be
Aspira Women's Health Inc. ( NASDAQ:AWH ) shareholders will doubtless be very grateful to see the share price up 70% in...